Lilly's ramucirumab meets OS endpoint in gastric cancer

Eli Lilly and Co. (NYSE:LLY) said ramucirumab met the primary endpoint in the Phase III REGARD

Read the full 168 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE